REAL-WORLD UTILISATION AND CLINICAL OUTCOMES OF PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER TREATED WITH OLAPARIB IN THE FIRST-LINE MAINTENANCE SETTING: 2-YEAR CLINICAL OUTCOMES OF THE PAN-EUROPEAN OVAL-1 STUDY

被引：0

作者：

Lorusso, Domenica ^{[1
,2
]}

Garbay, Delphine ^{[3
]}

Asselain, Bernard Jean Roger ^{[4
]}

Miller, Rowan ^{[5
,6
]}

Raspagliesi, Francesco ^{[7
]}

Zamagni, Claudio ^{[8
]}

Leary, Alexandra ^{[9
]}

Bellier, Charlotte ^{[10
]}

Glasspool, Ros ^{[11
,12
]}

Jayson, Gordon ^{[13
,14
]}

Grevat, Emmanuelle ^{[15
]}

Kertous, Mehdi ^{[15
]}

Sabatucci, Ilaria ^{[16
]}

Padrone, Claudia ^{[16
]}

Jayia, Parveen ^{[17
]}

Hada, Manila ^{[18
]}

Mclaurin, Kimmie ^{[18
]}

Gourley, Charlie ^{[19
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Scienze Salute Donna, Bambino & Sanita Pubbl, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Clin Tivoli Ducos, Bordeaux, France

[4] ARCAGY GINECO, Paris, France

[5] Univ Coll London Hosp, London, England

[6] St Bartholomews Hosp, London, England

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[9] Inst Gustave Roussy, Villejuif, France

[10] Ctr Oscar Lambret, Dept Cancerol Gynecol & Senol, Lille, France

[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland

[12] Univ Glasgow, Glasgow, Scotland

[13] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Manchester, England

[14] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth, Manchester, England

[15] AstraZeneca, Paris, France

[16] AstraZeneca, Milan, Italy

[17] AstraZeneca, London, England

[18] AstraZeneca, Oncol Outcomes Res, Global Med Affairs Evidence Generat & External Al, Gaithersburg, MD USA

[19] Univ Edinburgh, Canc Res UK Scotland Ctr, Edinburgh, Scotland

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷

关键词：

D O I：

10.1136/ijgc-2023-ESGO.895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

512

引用

页码：A426 / A426

页数：1

共 50 条

[41] Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer (MBC) treated with pertuzumab (P) in the first-line in a real-world setting
Robert, N.
Goertz, H. P.
Asmar, L.
Tseng, W. Y.
Jiao, X.
Portera, C.
Yoo, B.
Patt, D.
Antao, V.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S288 - S288
[42] Reasons for first-line maintenance therapy discontinuation among patients with newly diagnosed advanced ovarian cancer treated in real-world settings
Liu, Jinan
Thaker, Premal H.
Sah, Janvi
Maiese, Eric M.
Kalilani, Linda
Mallampati, Rajesh
Hurteau, Jean
Chan, John
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
[43] Real-world response rates and clinical outcomes of patients treated with first-line (1L) platinum-based chemotherapy (PBC) in advanced urothelial cancer (aUC).
Moon, Helen H.
Aragon-Ching, Jeanny B.
Thompson, Allison
Abraham, Anup
Vlahiotis, Anna
Ike, Chiemeka
Benjumea, Darrin
Shao, Anran
Sun, Haiyan
Kearney, Mairead
Gharibian, Norbek
Hanson, Sarah
Li, Benjamin
Kirker, Melissa
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[44] FIRST-LINE MAINTENANCE AMONG ADVANCED OVARIAN CANCER PATIENTS IN THE US ONCOLOGY NETWORK: A REAL-WORLD RETROSPECTIVE COHORT STUDY
Chase, Dana
Liu, Jinan
Moore-Schiltz, Laura
Perhanidis, Jennifer
Bulsara, Purva
Patton, Gregory
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A33 - A33
[45] Real-world clinical outcomes among patients with advanced non-small cell lung cancer who initiated first-line regimens
Nadler, Eric
Arondekar, Bhakti
Aguilar, Kathleen
Zhou, Jie
Chang, Jane
Zhang, Xinke
Pawar, Vivek
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[46] Real-World Analysis of Clinical Characteristics and Survival Outcomes in Patients With Extensive-Stage SCLC Treated With First-Line Chemoimmunotherapy
Wang, Yang
Mathai, Jared
Alamgeer, Muhammad
Parakh, Sagun
Paul, Eldho
Mitchell, Paul
Arulananda, Surein
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (08):
[47] The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Duska, Linda R.
Lim, Jonathan
Boyle, Tirza Areli Calderon
Guinter, Mark
Halloran, Siobhan
Hartman, John
Schilder, Jeanne M.
Hurteau, Jean A.
Golembesky, Amanda
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study
Tian, Panwen
Wu, Lin
Zhou, Chengzhi
Tan, Jie
Wang, Ke
Luo, Feng
Liu, Yongmei
Guo, Yubiao
Li, Yinyin
Liu, Zhe
Gong, Youling
Wang, Yongsheng
Li, Weimin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Comprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting
Sadetsky, N.
Lambert, P.
Julian, C.
Chen, J.
Yan, Y.
ANNALS OF ONCOLOGY, 2019, 30
[50] Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
Thaker, Premal H.
Boyle, Tirza Areli Calderon
Burns, Sara
Lim, Jonathan
Hartman, John
Kalilani, Linda, V
Schilder, Jeanne M.
Hurteau, Jean A.
Golembesky, Amanda K.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024,

← 1 2 3 4 5 →